Yousif Capital Management LLC Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Yousif Capital Management LLC trimmed its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,570 shares of the company’s stock after selling 207 shares during the period. Yousif Capital Management LLC’s holdings in Krystal Biotech were worth $1,725,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of KRYS. Principal Financial Group Inc. boosted its stake in Krystal Biotech by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock valued at $19,340,000 after acquiring an additional 3,727 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Krystal Biotech by 27.3% in the 4th quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company’s stock valued at $1,000,000 after purchasing an additional 1,369 shares during the period. Raymond James Financial Inc. purchased a new position in Krystal Biotech during the 4th quarter worth approximately $15,989,000. JPMorgan Chase & Co. grew its stake in Krystal Biotech by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company’s stock worth $23,786,000 after buying an additional 23,934 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Krystal Biotech by 1.8% during the fourth quarter. Federated Hermes Inc. now owns 13,048 shares of the company’s stock worth $2,044,000 after buying an additional 229 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital reaffirmed a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Finally, Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $211.13.

Krystal Biotech Stock Down 2.9%

NASDAQ KRYS opened at $133.04 on Tuesday. The stock has a market capitalization of $3.84 billion, a P/E ratio of 44.49 and a beta of 0.65. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The firm has a 50-day moving average price of $146.06 and a 200 day moving average price of $160.56.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. On average, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).